2025-12-04 - Analysis Report
Okay, let's break down the analysis of Merck & Co. (MRK) based on the provided data.

**0) Report Structure:**

I'll present the data first, followed by simple analysis for each section. Finally, a comprehensive summary will tie everything together.

**1) Return Rate Comparison:**

*   **Ticker:** MRK
*   **Company:** Merck & Co Inc (A global pharmaceutical company focused on research, development, manufacturing, and marketing of a wide range of healthcare products.)
*   **MRK Cumulative Return:** 20.98%
*   **VOO (S&P 500) Cumulative Return:** 100.36%
*   **Divergence:** -78.1 (Relative Divergence: 20.4)

**Analysis:**

*   MRK has significantly underperformed the S&P 500 over the tracked period.
*   The divergence is large and negative, indicating substantial underperformance.
*   The relative divergence of 20.4 suggests that MRK's current underperformance is near the bottom of its historical range compared to the S&P 500. In other words, the underperformance hasn't been this bad in the past, relatively speaking.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta  | Cap(B) |
|------------|--------|-------|---------|-------|--------|
| 2015-2017  | 1.0%   | 68.5% | -28.0%  | 0.0   | 134.1  |
| 2016-2018  | 36.0%  | 69.8% | 21.0%   | -0.0  | 182.1  |
| 2017-2019  | 40.0%  | 69.8% | 18.0%   | 0.3   | 216.8  |
| 2018-2020  | 16.0%  | 79.6% | -8.0%   | 0.3   | 194.9  |
| 2019-2021  | 2.0%   | 79.6% | -44.0%  | 0.7   | 191.4  |
| 2020-2022  | 15.0%  | 79.6% | 16.0%   | 0.7   | 277.1  |
| 2021-2023  | 33.0%  | 79.6% | 31.0%   | 0.3   | 272.3  |
| 2022-2024  | -4.0%  | 79.6% | -25.0%  | 0.2   | 248.5  |
| 2023-2025  | -28.0% | 71.5% | -93.0%  | 1.7   | 256.1  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Varies significantly, with periods of high growth (e.g., 2017-2019) and significant decline (2023-2025).
*   **MDD (Maximum Drawdown):**  High across the board, indicating significant potential for losses.
*   **Alpha:**  Highly variable. Negative Alpha means MRK underperformed relative to its Beta. The most recent period (2023-2025) shows a very large negative alpha, suggesting substantial underperformance relative to the market.
*   **Beta:** Fluctuates, but there is a significant increase in Beta for the 2023-2025 period, implying that the stock price is now more volatile than that of the market.
*   **Cap(B):** Market capitalization in billions. It shows the market capitalization over time.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 102.52
*   **Last-market:** price: 102.5, previousClose: 101.03, change: 1.46
*   **5-day SMA:** 103.712
*   **20-day SMA:** 94.5922
*   **60-day SMA:** 87.9087

**Analysis:**

*   The stock is currently trading above its 20-day and 60-day moving averages but below its 5-day moving average.
*   The 5-day SMA being above the 20-day SMA which is above the 60-day SMA suggest that the stock is in an uptrend.

**3) RSI, PPO, and Market Risk Indicators:**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 73.60 (Overbought)
*   **PPO (Percentage Price Oscillator):** 0.745
*   **Hybrid Signal:** Buy 100% of cash.
*   **Recent (20 days) relative divergence change:** 1.9 (+): short-term rise
*   **Expected Return (%):** -36.4% (Negative long-term outlook compared to S&P 500)

**Analysis:**

*   The MRI suggests a high investment recommendation, which seems contradictory given the other data.
*   The RSI indicates that the stock is currently overbought, suggesting a potential pullback.
*   PPO is positive, which indicates that the short-term price momentum is bullish.
*   The positive divergence change over the last 20 days reflects a short-term upward trend.
*   The significantly negative expected return is a major red flag.

**4) Recent News & Significant Events:**

*   A mix of news: Some positive (FDA wins, dividend hike, surprise win), some cautious (long road ahead, volatility), and some focused on geopolitical influence.
*   The headlines point to a complex situation with potential positive catalysts but also underlying concerns.

**Analysis:**

*   The news is mixed, showing that there are both positive and negative factors influencing the stock.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.97)
*   **Target Price:** Avg: 105.35 / High: 139.00 / Low: 82.00

**Analysis:**

*   Analysts, on average, have a "Buy" rating on the stock.
*   The average target price is slightly above the current price, suggesting some potential upside. However, the range is wide, indicating uncertainty.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$  |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2025-11-05 | 1.25 | 16.66 B$  |

**Analysis:**

*   EPS (Earnings Per Share) has generally been increasing in recent quarters, especially the most recent quarter.
*   Revenue shows a general upward trend.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.28B    | 77.69%        |
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |

**Analysis:**

*   Revenue is showing a strong upward trend.
*   Profit margins are consistently very high, indicating strong pricing power or cost control.

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30   | $51.85B    | 11.16%  |
| 2025-06-30   | $48.99B    | 9.04%   |
| 2025-03-31   | $48.34B    | 10.51%  |
| 2024-12-31   | $46.31B    | 8.08%   |
| 2024-09-30   | $44.50B    | 7.09%   |

**Analysis:**

*   Equity is steadily increasing, indicating growth in the company's net worth.
*   ROE (Return on Equity) is also increasing, reflecting improved profitability relative to equity.

**7) Comprehensive Analysis (Summary):**

*   **Underperformance:** MRK has significantly underperformed the S&P 500.
*   **Mixed Signals:** The MRI suggests a strong buy, but the expected return is very negative, creating a contradiction. The RSI also suggests that the stock is overbought.
*   **Short-Term Uptrend:** Recent price action suggests a short-term uptrend, but the analyst ratings show some uncertainty.
*   **Strong Fundamentals:** Revenue, profit margins, equity, and ROE are all showing positive trends. However, the long-term expected return is negative, which offsets the earnings trend.
*   **Analyst Optimism:** Analysts have a generally positive outlook, but the target price range is wide.
*   **News Catalyst:** The news indicates potential positive catalysts (FDA wins, dividend), but also underlying concerns about volatility.
*   **2023-2025 Period:** In recent years, the CAGR, Alpha, and MDD worsened, while the Beta grew rapidly.

**Conclusion:**

MRK presents a mixed picture. While the company's recent financial performance (revenue, profit margins, ROE) is strong, it has significantly underperformed the market, and the expected long-term return is negative. The MRI is contradictory, and the RSI suggests the stock is overbought. Analyst opinions are generally positive, but the wide target price range suggests uncertainty.

**Recommendation:**

**Based on this data, a cautious approach is warranted. Further investigation is needed to understand the negative expected return and the high market drawdown. The current analyst opinions suggest MRK as a buy but the recommendation for caution still stands.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.